Mycobacterium bovis BCG-based vaccines against tuberculosis: novel developments.

[1]  H. Mollenkopf,et al.  Cultivation of Mycobacterium bovis BCG in bioreactors. , 2002, Journal of biotechnology.

[2]  Y. Luo,et al.  Recombinant bacille Calmette–Guérin (BCG) expressing human interferon‐alpha 2B demonstrates enhanced immunogenicity , 2001, Clinical and experimental immunology.

[3]  M. Horwitz,et al.  Recombinant bacillus calmette-guerin (BCG) vaccines expressing the Mycobacterium tuberculosis 30-kDa major secretory protein induce greater protective immunity against tuberculosis than conventional BCG vaccines in a highly susceptible animal model. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[4]  W. Jacobs,et al.  Identification of a Mycobacterium bovisBCG Auxotrophic Mutant That Protects Guinea Pigs against M. bovis and Hematogenous Spread of Mycobacterium tuberculosis without Sensitization to Tuberculin , 2000, Infection and Immunity.

[5]  O. Neyrolles,et al.  Deletion of the 19kDa antigen does not alter the protective efficacy of BCG. , 2000, Tubercle and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[6]  I. N. Brown,et al.  Bacille Calmette–Guérin (BCG)‐associated inflammation and fibrosis: modulation by recombinant BCG expressing interferon‐gamma (IFN‐γ) , 2000, Clinical and experimental immunology.

[7]  G. Schoolnik,et al.  Comparative genomics of BCG vaccines by whole-genome DNA microarray. , 1999, Science.

[8]  P. Gounon,et al.  Attenuation of virulence by disruption of the Mycobacterium tuberculosis erp gene. , 1998, Science.

[9]  R. M. Simpson,et al.  The 16-kDa alpha-crystallin (Acr) protein of Mycobacterium tuberculosis is required for growth in macrophages. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[10]  S. Kaufmann,et al.  Mycobacterium bovis Bacille Calmette-Guérin strains secreting listeriolysin of Listeria monocytogenes. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[11]  W. Jacobs,et al.  Auxotrophic vaccines for tuberculosis , 1996, Nature Medicine.

[12]  R. Young,et al.  Manipulation and potentiation of antimycobacterial immunity using recombinant bacille Calmette-Guérin strains that secrete cytokines. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[13]  F. Mosteller,et al.  Efficacy of BCG Vaccine in the Prevention of Tuberculosis: Meta-analysis of the Published Literature , 1994 .

[14]  T. Kim.  High-viability lyophilized Bacille Calmette-Guérin vaccine produced by deep-culture technique , 1977, Applied and environmental microbiology.

[15]  P. Hemert.  Vaccine productions as a unit process , 1971 .

[16]  R. Dubos,et al.  PRODUCTION OF BCG VACCINE IN A LIQUID MEDIUM CONTAINING TWEEN 80 AND A SOLUBLE FRACTION OF HEATED HUMAN SERUM , 1950, The Journal of experimental medicine.

[17]  P. Fine,et al.  The BCG Experience: Implications for Future Vaccines against Tuberculosis , 1994 .

[18]  B. Bloom,et al.  Tuberculosis Pathogenesis, Protection, and Control , 1994 .

[19]  J. Gibson,et al.  Quality control of BCG vaccine by WHO: a review of factors that may influence vaccine effectiveness and safety. , 1990, Bulletin of the World Health Organization.

[20]  J. Nyabenda,et al.  The production of mycobacterial antigens by homogeneous culture in a fermentor. , 1988, Journal of biological standardization.

[21]  P. Lagrange,et al.  The stability and immunogenicity of a dispersed-grown freeze-dried Pasteur BCG vaccine. , 1988, Journal of biological standardization.